Business Context and Reporting Period
Company: Lexicon Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 6, 2025
Reporting Period: Event-specific (November 6, 2025)
This filing addresses a correction regarding a prospectus supplement filed in connection with an Open Market Sale Agreement with Jefferies LLC. The Company is a smaller reporting company and non-accelerated filer.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on a regulatory correction rather than financial performance reporting.
Material Changes
Correction of Inadvertent Statement: The Company corrected a statement in a prospectus supplement filed on November 6, 2025. The supplement incorrectly stated that Ernst & Young LLP (EY) had audited the effectiveness of the Company's internal control over financial reporting as of December 31, 2024.
Clarification: As a smaller reporting company and non-accelerated filer, Lexicon Pharmaceuticals is exempt from the requirement to have an independent audit of internal controls. Consequently, EY did not perform such an audit, and no such audit was included in the report incorporated by reference into the Registration Statement.
Guidance, Outlook, and Risks
- Capital Markets Activity: The Company maintains an Open Market Sale Agreement (dated December 29, 2023) allowing it to sell up to $75,000,000 of common stock through Jefferies LLC.
- Legal Disclaimer: This Form 8-K does not constitute an offer to sell or a solicitation of an offer to buy shares under the Agreement.
- Regulatory Status: The filing clarifies the Company's compliance status regarding internal control audits under SEC rules for smaller reporting companies.
Investor Verification Checklist
- Verify the Company's status as a "smaller reporting company" and "non-accelerated filer" to confirm exemption from internal control audits.
- Review the corrected prospectus supplement (File No. 333-281208) to ensure the inaccurate statement regarding EY's audit scope is removed.
- Confirm the terms of the Open Market Sale Agreement with Jefferies LLC, specifically the $75,000,000 aggregate sales price limit.
- Check for any subsequent filings regarding the actual sale of shares under the Agreement.